Skip Nav Destination
Issues
15 November 2018
-
Cover Image
Cover Image
The cover shows HER2 localization (in green) in erlotinib-resistant lung cancer cells (nuclei shown in blue). Cells were treated for 24 hours with a mixture of cetuximab (anti-EGFR), trastuzumab (anti-HER2), and osimertinib, a third-generation EGFR kinase inhibitor. Note the intracellular location of HER2, which normally localizes to the plasma membrane. For details, see the article by Romaniello and colleagues on page 5610 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Review
Clinical Trials: Targeted Therapy
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma
Zeynep Eroglu; Y. Ann Chen; Geoffrey T. Gibney; Jeffrey S. Weber; Ragini R. Kudchadkar; Nikhil I. Khushalani; Joseph Markowitz; Andrew S. Brohl; Leticia F. Tetteh; Howida Ramadan; Gina Arnone; Jiannong Li; Xiuhua Zhao; Ritin Sharma; Lancia N.F. Darville; Bin Fang; Inna Smalley; Jane L. Messina; John M. Koomen; Vernon K. Sondak; Keiran S.M. Smalley
Author Choice
Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Laetitia Mauge; on behalf of the PREINSUT study group; Arnaud Mejean; on behalf of the PREINSUT study group; Laure Fournier; on behalf of the PREINSUT study group; Helena Pereira; on behalf of the PREINSUT study group; Marie-Christine Etienne-Grimaldi; on behalf of the PREINSUT study group; Emeline Levionnois; on behalf of the PREINSUT study group; Armelle Caty; on behalf of the PREINSUT study group; Sophie Abadie-Lacourtoisie; on behalf of the PREINSUT study group; Stéphane Culine; on behalf of the PREINSUT study group; Sylvestre Le Moulec; on behalf of the PREINSUT study group; Claude Linassier; on behalf of the PREINSUT study group; Christine Théodore; on behalf of the PREINSUT study group; Alain Ravaud; on behalf of the PREINSUT study group; Laurence Albiges; on behalf of the PREINSUT study group; Abel Grine; on behalf of the PREINSUT study group; Eric Tartour; on behalf of the PREINSUT study group; Gérard Milano; on behalf of the PREINSUT study group; Anne-Sophie Gille; on behalf of the PREINSUT study group; Virginie Verkarre; on behalf of the PREINSUT study group; Dominique Helley; on behalf of the PREINSUT study group; Stéphane Oudard; on behalf of the PREINSUT study group
Author Choice
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study
Edward S. Kim; Karen Kelly; Luis G. Paz-Ares; Pilar Garrido; Shadia Jalal; Daruka Mahadevan; Martin Gutierrez; Mariano Provencio; Eric Schaefer; Monte Shaheen; Erica L. Johnston; P. Kellie Turner; Siva Rama Prasad Kambhampati; Richard Beckmann; Anwar Hossain; William J. John; Jonathan W. Goldman
Clinical Trials: Immunotherapy
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin; Chihiro Morishima; Vamsidhar Velcheti; Jeffrey S. Miller; Sylvia M. Lee; Ann W. Silk; Shernan G. Holtan; Andreanne M. Lacroix; Steven P. Fling; Judith C. Kaiser; Jack O. Egan; Monica Jones; Peter R. Rhode; Amy D. Rock; Martin A. Cheever; Hing C. Wong; Marc S. Ernstoff
Author Choice
T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
Drew C. Deniger; Anna Pasetto; Paul F. Robbins; Jared J. Gartner; Todd D. Prickett; Biman C. Paria; Parisa Malekzadeh; Li Jia; Rami Yossef; Michelle M. Langhan; John R. Wunderlich; David N. Danforth; Robert P.T. Somerville; Steven A. Rosenberg
Precision Medicine and Imaging
Author Choice
Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Yuming Jiang; Jingjing Xie; Zhen Han; Wei Liu; Sujuan Xi; Lei Huang; Weicai Huang; Tian Lin; Liying Zhao; Yanfeng Hu; Jiang Yu; Qi Zhang; Tuanjie Li; Shirong Cai; Guoxin Li
Author Choice
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Gunther Boysen; Daniel N. Rodrigues; Pasquale Rescigno; George Seed; David Dolling; Ruth Riisnaes; Mateus Crespo; Zafeiris Zafeiriou; Semini Sumanasuriya; Diletta Bianchini; Joanne Hunt; Deirdre Moloney; Raquel Perez-Lopez; Nina Tunariu; Susana Miranda; Inês Figueiredo; Ana Ferreira; Rossitza Christova; Veronica Gil; Sara Aziz; Claudia Bertan; Flavia M. de Oliveira; Mark Atkin; Matthew Clarke; Jane Goodall; Adam Sharp; Theresa MacDonald; Mark A. Rubin; Wei Yuan; Christopher E. Barbieri; Suzanne Carreira; Joaquin Mateo; Johann S. de Bono
KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case–Control Study
Ghislaine Scelo; David C. Muller; Elio Riboli; Mattias Johansson; Amanda J. Cross; Paolo Vineis; Konstantinos K. Tsilidis; Paul Brennan; Heiner Boeing; Petra H.M. Peeters; Roel C.H. Vermeulen; Kim Overvad; H. Bas Bueno-de-Mesquita; Gianluca Severi; Vittorio Perduca; Marina Kvaskoff; Antonia Trichopoulou; Carlo La Vecchia; Anna Karakatsani; Domenico Palli; Sabina Sieri; Salvatore Panico; Elisabete Weiderpass; Torkjel M. Sandanger; Therese H. Nøst; Antonio Agudo; J. Ramón Quirós; Miguel Rodríguez-Barranco; Maria-Dolores Chirlaque; Timothy J. Key; Prateek Khanna; Joseph V. Bonventre; Venkata S. Sabbisetti; Rupal S. Bhatt
Translational Cancer Mechanisms and Therapy
Author Choice
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
Donatella Romaniello; Luigi Mazzeo; Maicol Mancini; Ilaria Marrocco; Ashish Noronha; Matthew Kreitman; Swati Srivastava; Soma Ghosh; Moshit Lindzen; Tomer Meir Salame; Amir Onn; Jair Bar; Yosef Yarden
Author Choice
Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration
Qiuli Liu; Dali Tong; Gaolei Liu; Jie Gao; Lin-ang Wang; Jing Xu; Xingxia Yang; Qiubo Xie; Yiqiang Huang; Jian Pang; Luofu Wang; Yong He; Dianzheng Zhang; Qiang Ma; Weihua Lan; Jun Jiang
Author Choice
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Maryou B. Lambros; George Seed; Semini Sumanasuriya; Veronica Gil; Mateus Crespo; Mariane Fontes; Rob Chandler; Niven Mehra; Gemma Fowler; Berni Ebbs; Penny Flohr; Susana Miranda; Wei Yuan; Alan Mackay; Ana Ferreira; Rita Pereira; Claudia Bertan; Ines Figueiredo; Ruth Riisnaes; Daniel Nava Rodrigues; Adam Sharp; Jane Goodall; Gunther Boysen; Suzanne Carreira; Diletta Bianchini; Pasquale Rescigno; Zafeiris Zafeiriou; Joanne Hunt; Deirdre Moloney; Lucy Hamilton; Rui P. Neves; Joost Swennenhuis; Kiki Andree; Nikolas H. Stoecklein; Leon W.M.M. Terstappen; Johann S. de Bono
MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Michaël H. Meel; Mark C. de Gooijer; Miriam Guillén Navarro; Piotr Waranecki; Marjolein Breur; Levi C.M. Buil; Laurine E. Wedekind; Jos W.R. Twisk; Jan Koster; Rintaro Hashizume; Eric H. Raabe; Angel Montero Carcaboso; Marianna Bugiani; Olaf van Tellingen; Dannis G. van Vuurden; Gertjan J.L. Kaspers; Esther Hulleman
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Kyung-A Song; Yasuyuki Hosono; Crystal Turner; Sheeba Jacob; Timothy L. Lochmann; Yoshiko Murakami; Neha U. Patel; Jungoh Ham; Bin Hu; Krista M. Powell; Colin M. Coon; Brad E. Windle; Yuko Oya; Jennifer E. Koblinski; Hisashi Harada; Joel D. Leverson; Andrew J. Souers; Aaron N. Hata; Sosipatros Boikos; Yasushi Yatabe; Hiromichi Ebi; Anthony C. Faber
Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma
Jun S. Wei; Igor B. Kuznetsov; Shile Zhang; Young K. Song; Shahab Asgharzadeh; Sivasish Sindiri; Xinyu Wen; Rajesh Patidar; Sushma Najaraj; Ashley Walton; Jaime M. Guidry Auvil; Daniela S. Gerhard; Aysen Yuksel; Daniel Catchpoole; Stephen M. Hewitt; Paul M. Sondel; Robert Seeger; John M. Maris; Javed Khan
Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma
Aras Toker; Linh T. Nguyen; Simone C. Stone; S.Y. Cindy Yang; Sarah Rachel Katz; Patricia A. Shaw; Blaise A. Clarke; Danny Ghazarian; Ayman Al-Habeeb; Alexandra Easson; Wey L. Leong; David R. McCready; Michael Reedijk; Cynthia J. Guidos; Trevor J. Pugh; Marcus Q. Bernardini; Pamela S. Ohashi
Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Adrián González-González; Esperanza Muñoz-Muela; Juan A. Marchal; Francisca E. Cara; Maria P. Molina; Marina Cruz-Lozano; Gema Jiménez; Akanksha Verma; Alberto Ramírez; Wei Qian; Wen Chen; Anthony J. Kozielski; Olivier Elemento; María D. Martín-Salvago; Rafael J. Luque; Carmen Rosa-Garrido; David Landeira; María Quintana-Romero; Roberto R. Rosato; Maria A. García; Cesar L. Ramirez-Tortosa; Hanna Kim; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K. Sood; Jose A. Lorente; Pedro Sánchez-Rovira; Jenny C. Chang; Sergio Granados-Principal
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
Jérôme Biton; Audrey Mansuet-Lupo; Nicolas Pécuchet; Marco Alifano; Hanane Ouakrim; Jennifer Arrondeau; Pascaline Boudou-Rouquette; François Goldwasser; Karen Leroy; Jeremy Goc; Marie Wislez; Claire Germain; Pierre Laurent-Puig; Marie-Caroline Dieu-Nosjean; Isabelle Cremer; Ronald Herbst; Hélène Blons; Diane Damotte
Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma
Bradley W. Anderson; Yun-Suhk Suh; Boram Choi; Hyuk-Joon Lee; Tracy C. Yab; William R. Taylor; Brian A. Dukek; Calise K. Berger; Xiaoming Cao; Patrick H. Foote; Mary E. Devens; Lisa A. Boardman; John B. Kisiel; Douglas W. Mahoney; Seth W. Slettedahl; Hatim T. Allawi; Graham P. Lidgard; Thomas C. Smyrk; Han-Kwang Yang; David A. Ahlquist
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti–PD1-Resistant Lung Tumor Model
Sharareh Niknam; Hampartsoum B. Barsoumian; Jonathan E. Schoenhals; Heather L. Jackson; Niranjan Yanamandra; Mauricio S. Caetano; Ailin Li; Ahmed I. Younes; Alexandra Cadena; Taylor R. Cushman; Joe Y. Chang; Quynh N. Nguyen; Daniel R. Gomez; Adi Diab; John V. Heymach; Patrick Hwu; Maria Angelica Cortez; James W. Welsh
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma
Luc Cabel; Emmanuelle Jeannot; Ivan Bieche; Sophie Vacher; Celine Callens; Louis Bazire; Adeline Morel; Alice Bernard-Tessier; Walid Chemlali; Anne Schnitzler; Astrid Lièvre; Joelle Otz; Mathieu Minsat; Anne Vincent-Salomon; Jean-Yves Pierga; Bruno Buecher; Pascale Mariani; Charlotte Proudhon; François-Clément Bidard; Wulfran Cacheux
LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Carmen Dorneburg; Matthias Fischer; Thomas F.E. Barth; Wolfgang Mueller-Klieser; Barbara Hero; Judith Gecht; Daniel R. Carter; Katleen de Preter; Benjamin Mayer; Lisa Christner; Frank Speleman; Glenn M. Marshall; Klaus-Michael Debatin; Christian Beltinger
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.